Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Optical Activity | ( + ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCCC[C@]13CCN(C)[C@H]2CC4=CC=C(OC)C=C34
InChI
InChIKey=MKXZASYAUGDDCJ-NJAFHUGGSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27139517Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2694543
http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25420446
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2694543
http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25420446
Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24678061
Curator's Comment: # in a Swiss and US patent application from Hoffmann-La Roche in 1946 and 1947, respectively
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099 |
205.0 nM [Ki] | ||
Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MUCINEX DM Approved UseHelps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date1.08319677E12 |
|||
Primary | NUEDEXTA Approved UseNUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date1.28580479E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEXTRORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217 |
30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered: |
DEXTROMETHORPHAN plasma | Homo sapiens population: healthy age: adults sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/ |
30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE |
DEXTROMETHORPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: |
unhealthy, 19-52 years n = 16 Health Status: unhealthy Condition: chronic intractable partial onset seizures Age Group: 19-52 years Sex: M+F Population Size: 16 Sources: |
|
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: |
unhealthy, 19-67 years n = 11 Health Status: unhealthy Condition: Huntington's disease Age Group: 19-67 years Sex: M+F Population Size: 11 Sources: |
|
120 mg single, oral Recommended |
healthy, 26.5 years n = 40 Health Status: healthy Age Group: 26.5 years Sex: M+F Population Size: 40 Sources: |
|
900 mg single, oral Overdose |
unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: |
Other AEs: Ischemic colitis... |
270 mg single, oral Overdose |
unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: |
Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Sources: Ataxia (1 patient) Nystagmus (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | 1 patient | 900 mg single, oral Overdose |
unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: M Population Size: 1 Sources: |
Ataxia | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: |
Lethargy | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: |
Nystagmus | 1 patient | 270 mg single, oral Overdose |
unknown, 3 years n = 1 Health Status: unknown Age Group: 3 years Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no | |||
Page: 14.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0 |
PubMed
Title | Date | PubMed |
---|---|---|
The need for rational therapeutics in the use of cough and cold medicine in infants. | 1992 Apr |
|
Visual hallucinations after combining fluoxetine and dextromethorphan. | 1992 Oct |
|
Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. | 1999 Apr |
|
Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. | 1999 Jul 14 |
|
Gamma-aminobutyric acid and glutamic acid receptors may mediate theophylline-induced seizures in mice. | 1999 Mar |
|
Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. | 1999 Mar 13 |
|
Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: case report. | 1999 Mar-Apr |
|
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches. | 2001 |
|
Prediction models in the design of neural network based ECG classifiers: a neural network and genetic programming approach. | 2002 |
|
A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition. | 2002 Aug 22 |
|
Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. | 2002 Dec |
|
Bridging sectors. Medicon Valley. | 2002 Dec 12 |
|
Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. | 2002 Jul-Aug |
|
Biotechnology in the Medicon Valley. | 2002 May |
|
Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. | 2003 Feb 15 |
|
Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. | 2003 Sep-Oct |
|
Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. | 2004 Apr |
|
Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. | 2004 Jul |
|
Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. | 2004 Jul |
|
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens. | 2004 Jul 16 |
|
Validated assays for human cytochrome P450 activities. | 2004 Jun |
|
Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice. | 2004 May 5 |
|
Bladder emptying over a period of 10-45 years after a traumatic spinal cord injury. | 2004 Nov |
|
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico. | 2005 |
|
Epigenetic silencing of DSC3 is a common event in human breast cancer. | 2005 |
|
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. | 2005 |
|
Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. | 2005 Feb |
|
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. | 2005 Jul 19 |
|
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. | 2005 Jun |
|
Dextromethorphan-induced delirium and possible methadone interaction. | 2005 Mar |
|
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris. | 2005 Nov |
|
Side effects of dextromethorphan abuse, a case series. | 2005 Sep |
|
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings. | 2006 Jun 27 |
|
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan. | 2006 Nov-Dec |
|
Treatment of the common cold. | 2007 Feb 15 |
|
A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. | 2007 Jan |
|
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. | 2007 Jul |
|
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. | 2007 Jul |
|
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method]. | 2007 Jun |
|
Effect of sodium ozagrel on the activity of rat CYP2D6. | 2007 Nov 14 |
|
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. | 2007 Spring |
|
Ubiquitous computing for remote cardiac patient monitoring: a survey. | 2008 |
|
Effects of common antitussive drugs on the hERG potassium channel current. | 2008 Dec |
|
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice. | 2008 Jul |
|
Amyotrophic lateral sclerosis. | 2009 Feb 3 |
|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. | 2009 Jan |
|
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy. | 2009 Jan-Feb |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/1503667
https://www.ncbi.nlm.nih.gov/pubmed/26000221
15-30 mg 3 to 4 times per day (cough)
20-30 mg twice daily (pseudobulbar affect)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24912029
In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:04:42 UTC 2023
by
admin
on
Fri Dec 15 15:04:42 UTC 2023
|
Record UNII |
7355X3ROTS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000181821
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
CFR |
21 CFR 341.14
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
CFR |
21 CFR 341.74
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
WHO-VATC |
QN07XX59
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
WHO-VATC |
QR05DA09
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
WHO-ATC |
R05DA09
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
NDF-RT |
N0000182149
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
WHO-ATC |
N07XX59
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
||
|
NCI_THESAURUS |
C2199
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1180503
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
C62022
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
751452
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
m4227
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | Merck Index | ||
|
166
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
N0000181819
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | Uncompetitive NMDA Receptor Antagonists [MoA] | ||
|
4470
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
DTXSID3022908
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
3056
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
125-71-3
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
SUB07051MIG
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
204-752-2
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
CHEMBL52440
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
N0000182147
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | Sigma-1 Receptor Agonists [MoA] | ||
|
842
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
DB00514
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
6953
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
7355X3ROTS
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
Dextromethorphan
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
7355X3ROTS
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
3289
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
ALTERNATIVE | RxNorm | ||
|
DEXTROMETHORPHAN
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
100000092321
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
D003915
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
5360696
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY | |||
|
236146
Created by
admin on Fri Dec 15 15:04:42 UTC 2023 , Edited by admin on Fri Dec 15 15:04:42 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Metabolizing reaction by CYP2D6: O-demethylation
Pharmacological action: Antitusive agent
MAJOR
Unidentified
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->WEAK INHIBITOR |
Rat. Prodrug of dextrorphan, which is the actual mediator of most of its dissociative effects through acting as a more potent NMDA receptor antagonist than dextromethorphan itself.
Ki
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
Rat
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT |
SECONDARY METABOLITE CYP3A4 ALSO INVOLED IN PRIMARY
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|